PIK3CA and neoplasm: Similarly, targeting the PI3K pathway in mouse models with PTEN loss by using a selective small molecule inhibitor improved T cell-induced tumor killing and efficacy of immunotherapy with anti PD-1 and anti-CTLA4 treatments [29].